会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 131. 发明授权
    • Compositions and methods for non-parenteral delivery of oligonucleotides
    • 用于非肠胃外递送寡核苷酸的组合物和方法
    • US06747014B2
    • 2004-06-08
    • US10029598
    • 2001-12-21
    • Ching-Leou TengPhillip Dan CookLloyd TillmanGregory E. HardeeDavid J. EckerMuthiah Manoharan
    • Ching-Leou TengPhillip Dan CookLloyd TillmanGregory E. HardeeDavid J. EckerMuthiah Manoharan
    • A61K3170
    • A61K48/0075A61K9/0014A61K9/0019A61K47/12A61K47/28A61K48/00C07H21/00Y10S514/946
    • The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes. The compositions and methods of the invention are utilized to effect the oral, buccal, rectal or vaginal administration of an antisense oligonucleotide to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic, palliative or prophylactic purposes.
    • 本发明涉及通过非肠胃外给药途径增强寡核苷酸和核酸的局部和全身摄取和递送的组合物和方法。 包含本文公开的寡核苷酸的药物组合物包括用于全身递送的乳液和微乳液制剂用于各种应用和口服剂型。 还令人惊讶地发现,可以用简单的溶液,例如纯的或盐水,通过直肠灌肠剂和栓剂将寡核苷酸局部递送至结肠部位。 寡核苷酸的这种药物组合物可以进一步包括一种或多种用于将寡核苷酸和其它核酸转移穿过粘膜的渗透增强剂。 本发明的组合物和方法用于对动物进行口服,口腔,直肠或阴道施用反义寡核苷酸,以调节动物中基因在调查,治疗,姑息或预防目的中的表达。
    • 132. 发明授权
    • In situ binary synthesis of biologically effective molecules
    • 生物有效分子的原位二元合成
    • US06492111B1
    • 2002-12-10
    • US09200107
    • 1998-11-25
    • David J. Ecker
    • David J. Ecker
    • C12Q168
    • C12N15/113A61K38/00C12N2310/351C12Q1/6841Y02A50/469C12Q2565/101
    • A plurality of oligonucleotides are caused to bind specifically to target nucleic acid which is predictive of a disease state or a biological condition within cells containing the target nucleic acid. The respective oligonucleotides, which may be functionilized or may be present in the form of oligonucleotide analogs, carry with them a plurality of synthons. Such synthons, which may be identiphores, toxiphores, or other precursors to biologically effective molecules, interact when specific binding of the respective oligonucleotides occurs at sites adjacent to each other on the target nucleic acid. The resulting interaction gives rise to the synthesis, generation or release of highly active biological molecules in situ in the cell in which the specific binding takes place. This permits the use of extraordinarily toxic molecules for use in killing cells containing the target nucleic acids. Imaging and other uses are also provided by the present invention.
    • 导致多个寡核苷酸特异性结合预测含有靶核酸的细胞内的疾病状态或生物学条件的靶核酸。 可以被功能化或可以寡核苷酸类似物形式存在的各个寡核苷酸携带多个合成子。 当相应寡核苷酸的特异性结合发生在靶核酸上彼此相邻的位点时,这种可能是识别的氨基酸,毒素或生物有效分子的其它前体相互作用。 所产生的相互作用导致在发生特异性结合的细胞中原位生成高度活性的生物分子的合成,产生或释放。 这允许使用非常有毒的分子用于杀死含有靶核酸的细胞。 成像和其他用途也由本发明提供。
    • 135. 发明授权
    • Oligonucleotides inhibiting candida germ tube formation
    • 抑制念珠菌胚管形成的寡核苷酸
    • US5691461A
    • 1997-11-25
    • US229145
    • 1994-04-18
    • David J. EckerGlenn D. Hoke
    • David J. EckerGlenn D. Hoke
    • A61K38/00C07K14/40C12N15/113C07H21/04
    • C12N15/113C07K14/40A61K38/00C12N2310/315
    • Compositions and methods are provided for the treatment and diagnosis of Candida infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with at least a portion of a Candida mRNA. Preferred targets are the mRNAs which encode .beta.-tubulin, aspartate protease, actin and chitin synthetase, as well as the mRNA's which encode the ribosomal L25 protein, translation elongation factors 1 and 2 (TEF1 and TEF2), the b subunit of ATPase, and cytochrome P450 lanosterol 14.alpha.-demethylase (L1A1). The oligonucleotides comprise nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3' untranslated sequences, 5' cap, and intron/exon junction of the mRNAs. Methods of treating animals suffering from Candida infection are disclosed.
    • 提供组合物和方法用于治疗和诊断念珠菌感染。 根据优选实施方案,提供了与至少一部分念珠菌mRNA特异性杂交的寡核苷酸。 优选的靶标是编码β-微管蛋白,天冬氨酸蛋白酶,肌动蛋白和几丁质合成酶的mRNA,以及编码核糖体L25蛋白的mRNA,翻译延伸因子1和2(TEF1和TEF2),ATP酶的b亚基和 细胞色素P450羊毛甾醇14α-甲基化酶(L1A1)。 寡核苷酸包含足以实现所述特异性杂交的同一性和数目的核苷酸单元。 在其它优选的实施方案中,寡核苷酸与mRNA的转录起始位点,翻译起始位点,5'-非翻译序列,3'非翻译序列,5'帽和内含子/外显子连接物特异性杂交。 公开了治疗念珠菌感染动物的方法。